TABLE 2.
Antiviral activity of WC5 against other herpesviruses
| Virus (strain) | Cell line | Controla
|
WC5
|
||||
|---|---|---|---|---|---|---|---|
| EC50 (μM)b | CC50 (μM)c | SId | EC50 (μM)b | CC50 (μM)c | SId | ||
| HHV-6A (GS) | HSB-2 | 6.6 ± 3.0 | 800 ± 150 | 121 | 5.1 ± 1.6 | 32 ± 6 | 6 |
| HHV-6B (Z29) | MOLT-3 | 4.3 ± 2.5 | 1,100 ± 150 | 256 | 3.3 ± 1.8 | 24 ± 8 | 7 |
| HHV-8 | BC-3 | 6.5 ± 1.2 | 256 ± 100 | 39 | 14.2 ± 7.3 | 47 ± 13 | 3 |
| MCMV (Smith) | NIH 3T3 | 0.4 ± 0.1 | 250 ± 10 | 625 | 10.8 ± 5.5 | 275 ± 25 | 25 |
a
For HHV-6A and HHV-6B, PFA was used; for HHV-8, GCV was used; and for MCMV, CDV was used.
b
EC50 was determined by quantification of viral DNA production by qPCR for HHV-6A, HHV-6B, and HHV-8 and by plaque reduction assays for MCMV. Reported values represent the means ± standard deviations (SD) of data derived from at least three independent experiments performed in duplicate.
c
CC50 was determined by MTT assays. Reported values represent the means ± SD of data derived from at least three independent experiments performed in quadruplicate.
d
SI was determined as the ratio between CC50 and EC50.